The description of the three-dimensional structure of the influenza virus neuraminidase in 1983 opened a new phase in the search for inhibitors of the enzyme. Two compounds in late development (February 1999) have similar levels of potency against influenza A viruses, different routes of administration and, surprisingly, different resistance profiles both in vitro and in vivo.